Posted on Leave a comment


Prof Judy Delp D'OXYVA how to increase blood flow in foot

Toriyama et al. studied the effect of CObathing in 83 limbs with critical ischemia and achieved limb salvage in 83% without surgery. They concluded that peripheral vasodilation from CObathing resulted from an increased parasympathetic and decreased sympathetic activity. Application of transdermal COproduces a remote vasodilation that may be mediated through release of a circulating humoral agent.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Recently, studies have documented that episodes of brief, non-damaging ischemia occurring in a tissue can induce systemic protection against ischemia-reperfusion injury in a remote organ. This phenomenon, termed remote ischemic conditioning, has been demonstrated to confer protection against ischemic events in the myocardium, brain, and kidney. Although shown to be effective in various clinical and preclinical models, the mechanism(s) of remote protection have not been clearly identified. Both neural and humoral mechanisms have been proposed to contribute to the protection against ischemic damage afforded by remote ischemic conditioning. Basalay et al. have shown that when remote ischemic conditioning is applied before induction of myocardial ischemia, sensory nerves and recruitment of a parasympathetic neural pathway are involved in reduction of infarct size.

Recently, Michelsen and colleagues have demonstrated that dialysate of human plasma from subjects who underwent either ischemic preconditioning or exercise preconditioning reduced infarct size in rabbit hearts, indicating that release of a humoral factor, contributes to the cardioprotective effects of ischemic and exercise preconditioning; however, these circulating substance(s) remain to be identified.

Future investigations will need to monitor heart rate, heart rate variability, and sympathetic nerve activity in order to more fully assess the role of the autonomic nervous system in mediating the sustained increases in SPP and systolic blood pressure reported in this initial study and focus on assessment of plasma samples during and following skin delivery COapplication. The D’OXYVA device is safe and can be administered at home. There are a lot of possibilities here and we are really excited about conducting future studies to determine what D’OXYVA may be able to provide to people with microvascular disease.

About Prof. Judy Delp

Prof. Judy Delp

Dr. Judy Delp is a Professor of Biomedical Sciences at Florida State University, she gained her PhD at University of Missouri. She is also a member of the American Physological Society, American Microcirculatory Society, American Heart Association. Prof. Judy Delp has co-authored 94 publications.


Blog Posts

physician-recommended, easy to use daily

Why Use D'OXYVA?

Increasing demand for painless drug delivery, coupled with rising demand for self-administration of drugs, is anticipated to fuel market growth. D’OXYVA® (deoxyhemoglobin vasodilator) is the only fully non-invasive, non-irritating, non-opioid, and completely painless, over-the-skin delivery nerve stimulant and microcirculatory solution with over seven years of industry-leading research results.

D’OXYVA® has been demonstrating for years that it does not break the skin’s barrier, while it provides exceptional quality of life and health benefits quickly and affordably.

In short, based on current leading neurology, immunology, microvascular, and cellular oxygenation science, D’OXYVA® is leading the field by significantly lowering the risk of diabetes and cardiovascular complications and providing complete and significant improvement of difficult wounds together with major pain relief and improved quality of life.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Was the article informative?